Abstract
Cytomegalovirus retinitis has been the most common opportunistic infection and leading cause of visual loss in AIDS patients. There are five drugs approved by the Food and Drug Administration in the USA for the treatment of cytomegalovirus retinitis: ganciclovir, foscarnet/phosphonoformic acid, valganciclovir, cidofovir and formivirsen. Progress has been made in the treatment of cytomegalovirus retinitis. Nowadays, maribavir, monoclonal antibody MSL-109, cyclopropavir and BAY 38-4766 are entering clinical trials. This review summarizes present status and advances in pharmacotherapy for cytomegalovirus retinitis in AIDS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.